Skip to Content

 

Over the last 10 or so years VivoBiotech have witnessed unprecedented discovery efforts to develop selective androgen receptor modulators (SARMs) & Peptides which will improve physical function, bone health and density without adversely affecting the prostate or cardiovascular output. SARM development is import to us at vivo, VivoBiotech are continuasly working to undertstand the mechanisms of testosterone and actions both SARMs and Peptides within the humun body.

Here at VivoBiotech we have also been progressing on researchng the psychotropic effects of cannabinoids which are principally mediated by CB1, which is widely distributed throughout the human brain, but it is mainly deployed into the frontal cortex, basal ganglia and cerebellum. CB1 has also been shown to be present in several tissues and organs, including the adipose tissue, the gastrointestinal tract, the spinal cord, adrenal and thyroid glands, liver and other reproductive organs and immune cells. We will continue to work hand in hand with rcnet-cheimicals who is a subdivisary of our company that specializes in in-vitro research procedures on all cannabinoids and research chemicals.

 


 

Company Mission


Vivo Biosciences Inc. (VBI), an early stage biotech company founded in 2004, has developed new ‘all-human’ bioassay platforms for preclinical research, drug discovery and therapeutics. The company relies on its patented HuBiogel™ technology which emulates the biology of normal and disease tissues in vitro. A series of 3-D or Mini-tumor bioassay systems are developed for rapid analysis of drug efficacy, toxicity and therapy prediction, the major bottlenecks of current drug development pipeline. This high-value technology is offered worldwide to academic, commercial and government institutions.


 

Dr. Singh, a well recognized cancer researcher,  is the founder of Vivo Biosciences and the principal developer of the company’s HuBiogel technology. He has established the proprietary protocols for HuBiogel production and bioassay systems. He has validated the tumorigenesis and angiogenesis assay models and created new 3D tissue-like functional models for drug discovery, therapeutic and toxicity research. He has received many significant top-scored SBIR and STTR grants and contracts. With more than 50 publications including a recent book chapter, he also has several US and International technology patents issued and pending.


  

Managing Partner, Fund Operations of Greer Capital Advisors (GCA). Mr. Dean has more than 20 years’ experience in all aspects of technology transfer, in both the non-profit and for-profit sectors.  Prior to joining GCA, Mr. Dean was Director of the University of Texas Health Science Center in San Antonio's Office of Technology Transfer, where he played a prominent role in the formation of numerous successful technology companies, and in greatly elevating licensing productivity.  Mr. Dean was also head of technology commercialization at Southern Research Institute, an institution known for its oncology drug discoveries, and led the team responsible for licensing Institute inventions and forming technology spin-offs.  He co-founded the drug-delivery company, Southern BioSystems, Inc., which was later acquired by a public company.   Mr. Dean sits on the board of CardioSpectra, Inc., one of Scout Health Care Fund's portfolio companies as well as BioDtech, one of the Birmingham Technology Fund's portfolio companies. 


 

Professor and Director of Center for Biophysical Sciences & Engineering, Director and a Senior Scientist at the University of Alabama at Birmingham Comprehensive Cancer Center X-ray Crystallography Facility, and a Professor in the Schools of Optometry, Biochemistry, and Physiology and Biophysics.  He is a recipient of the  UAB distinguished faculty award and the State of Alabama Howard Heflin Statesmanship Award for Technology Innovation.  Dr. DeLucas also served as an NASA astronaut serving as the payload specialists aboard the space shuttle Columbia and as the NASA Chief Scientist for the International Space Station .  Dr. DeLucas is a founding member of Vivo Biosciences Board of Directors. As a distinguished scientist, he serves as member of multiple biotechnology company boards.

 

Philip W. Faris, Jr., Board Member

CEO and managing partner at ProSavant International.  Faris has a distinguished track record of building market-leading companies in emerging medical markets and has successfully performed as CEO for over three decades in start-up, early stage, and high-growth organizations. He is currently CEO and managing partner at ProSavant International, a strategic consulting firm for the medical device and biotechnology spaces and is Executive Chairman of Innovative Trauma Care, Inc., an early stage medical device company focused on the treatment of major challenges in trauma care at the point of injury. He also serves on the Executive Committee of BiomedSA, a non-profit organization promoting the bioscience industry in San Antonio, Texas. Through his career, Faris has acted as CEO and Director at Vidacare Corporation, VidiMedix Corporation, Trestle Corporation, Diatek Corporation and many other medical device,  biotechnology and health care companies.

 

Get in touch with us